Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy
Highlights from SIOP 2026
STAS in Stage I Lung Adenocarcinoma Is More Than a Histologic Finding: Multi-Omic Profiling Reveals an Aggressive Molecular Phenotype
Robin Zon: ASCO Highlights Medicaid Policy Changes and Continuity of Cancer Care
Patrizia Giannatempo: A New Perioperative Era in MIBC
Atezolizumab Plus Gemcitabine/Cisplatin in Metastatic Urothelial Cancer
WHO Flags Six Essential Childhood Cancer Medicines Facing Critical Access Gaps
The Mayo Clinic Multidisciplinary Update in Breast Disease 2026 will take place from November 5–7, 2026, at the JW Marriott Austin in Austin, Texas, USA, with livestream participation available. The […]
